Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159219 | 0.86 | LMNA (0.63) | SMN1; SMN2LMNAGAAMEN1KMT2A | |
| SCHEMBL6044214 | 0.85 | MEN1 (0.57) | SMN1; SMN2LMNAMEN1KMT2AHTT | |
| SCHEMBL30899745 | 0.84 | MEN1 (0.58) | SMN1; SMN2LMNAMEN1KMT2AHTT | |
| SCHEMBL6827343 | 0.83 | LMNA (0.53) | SMN1; SMN2LMNAGAAMEN1KMT2A | |
| SCHEMBL20718021 | 0.82 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAGAAMEN1KMT2A | |
| SCHEMBL6829347 | 0.82 | LMNA (0.52) | SMN1; SMN2LMNAGAAMEN1KMT2A | |
| SCHEMBL25819360 | 0.81 | LIPE (0.50) | SMN1; SMN2LMNAGAAMEN1KMT2A | |
| SCHEMBL8703529 | 0.81 | KAT2B (0.58) | SMN1; SMN2LMNAHTTKAT2B | |
| SCHEMBL31287201 | 0.81 | GAA (0.58) | SMN1; SMN2LMNAGAAMEN1KMT2A | |
| SCHEMBL28546176 | 0.81 | LMNA (0.57) | SMN1; SMN2LMNAGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265669-A1 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS | BRAF, RAF1, NRAS | SMN1; SMN2 4530/4885LMNA 2578/4885GAA 4834/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | SMN1; SMN2 4550/4885LMNA 2643/4885GAA 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.